Adhansia XR (methylphenidate HCl extended-release capsules) is expected to be available by the end of July 2019 for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older, according to Adlon Therapeutics.
The treatment was granted approval by the Food and Drug Administration (FDA) in March 2019 following a review of 4 clinical trials evaluating its safety and efficacy in adult and pediatric patients.
Adhansia XR will be supplied in 25mg, 35mg, 45mg, 55mg, 70mg, and 85mg extended-release capsules; each bottle contains 30 capsules. Treatment is administered once daily in the morning. For patients who have difficulty swallowing, the contents of the capsule may be sprinkled onto a tablespoon of applesauce or yogurt; the dose of a single capsule should not be divided.
Adhansia XR contains methylphenidate, a Schedule II controlled substance. The product should not be substituted for other methylphenidate products on a milligram-per-milligram basis because of different methylphenidate base composition and differing pharmacokinetic profiles.
For more information visit adlontherapeutics.com.
This article originally appeared on MPR